Homegrown pharmaceutical firm Wockhardt on Tuesday said it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to export up to 10 crore doses of Russian COVID-19 vaccine Sputnik.
The approval is for the export of up to 8 crore doses of Sputnik Light and up to 2 crore doses of Sputnik V Component I vaccines, Wockhardt Ltd said in a regulatory filing.
The company's bulk vaccine and fill-finish manufacturing facilities at Waluj and Shendra, Aurangabad, were "jointly inspected and approved by Drug inspectors from CDSCO (West zone) and Aurangabad State FDA and expert from CDL (Central Drugs Laboratory) Kasauli" to receive the export NOC (no objection certificate), it added.
The state-of-the-art automated manufacturing facilities in Aurangabad are dedicated to producing world-class high-quality injectable products, the company said.
Wockhardt said it had entered into an agreement with the Russian Direct Investment Fund and Enso Healthcare to manufacture and supply Sputnik V and Sputnik Light vaccines against COVID-19 based on the technology transfer from Gamaleya National Research Institute of Epidemiology and Microbiology.
On Sunday, Union Health Minister Mansukh Mandaviya had announced that the Drugs Controller General of India has granted emergency use permission to single-dose Sputnik Light COVID vaccine in the country.
Last year in April, India's regulator had granted permission for restricted emergency use of the Russian COVID-19 vaccine Sputnik V with certain conditions.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU